# LakeShore Biopharma Co., Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/LakeShore Biopharma Co., Ltd.). ## Overview LakeShore Biopharma Co., Ltd. is a biopharmaceutical company focused on discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics. Its work centers on infectious diseases and cancer, with operations based in Beijing, China and a corporate listing structure that includes reporting in the United States. ## Products & services • Preventive vaccines • Therapeutic biologics • Infectious disease immunotherapies • Cancer-related biologics • PIKA® immunomodulating platform • Biopharmaceutical R&D and manufacturing - **Vaccines** (45%) — Preventive vaccine candidates and related vaccine products for infectious diseases. - **Therapeutic biologics** (35%) — Biologic therapies developed for infectious diseases and oncology indications. - **Platform technology** (10%) — PIKA® immunomodulating technology used to support vaccine and biologics development. - **Research and development services** (10%) — Preclinical and clinical development activities for internal and partnered programs. - Preventive vaccines - Therapeutic biologics - Infectious disease immunotherapies - Cancer-related biologics - PIKA® immunomodulating platform - Biopharmaceutical R&D and manufacturing ## Customers LakeShore Biopharma sells into public health, healthcare, and life-science channels that need vaccines or biologics for infectious disease prevention and treatment. Its products are ultimately used by patients, but procurement and adoption are driven by governments, healthcare systems, distributors, and clinical partners that evaluate efficacy, safety, and manufacturing capability. The business also depends on research collaborators and regulators because development-stage biologics require extensive clinical and approval pathways. - **Public health and government buyers** (primary) — Buy vaccines for disease prevention programs and outbreak response, where procurement depends on public health needs and regulatory approval. - **Hospitals and healthcare providers** (secondary) — Use therapeutic biologics and related products in treatment settings, typically based on clinical utility and reimbursement access. - **Distribution partners** (secondary) — Purchase or distribute products to extend market reach and support commercialization in multiple geographies. - **Research and clinical collaborators** (emerging) — Work with the company on development programs and platform technology, helping advance vaccine and biologics candidates. - Public health buyers seeking vaccine supply for disease prevention - Hospitals and healthcare systems using biologics in treatment settings - Distributors and commercialization partners for market access - Clinical researchers and collaborators supporting development programs - Patients as end users of approved vaccines and therapies ## Geography The company is headquartered in Beijing, China but reports as a foreign private issuer in the United States and has securities traded in U.S. over-the-counter markets. Its business is described as global, implying cross-border development, manufacturing, and commercialization exposure across multiple markets rather than a single-country operation. - **China** (50%) — Headquarters and principal executive offices are in Beijing; likely core operating base. - **United States** (20%) — U.S. reporting and OTC listing create a meaningful U.S. capital-markets presence. - **Rest of world** (30%) — Press releases describe the company as global, but no country split is disclosed. - Headquartered in Beijing, China - Reports to U.S. regulators as a foreign private issuer - OTC-listed in the United States - Global biopharmaceutical business with cross-border exposure - Operations likely tied to China-based R&D and manufacturing ## Strategy LakeShore Biopharma’s strategy appears centered on advancing vaccine and biologics programs built on its PIKA® immunomodulating platform. The reported merger activity suggests a major ownership or capital-structure transition, which can affect how the company funds development, commercializes products, and structures long-term growth. Its competitive position depends on moving programs through clinical development and into manufacturable, distributable products for infectious disease and oncology markets. - **Advance core vaccine and biologics pipeline** (medium-term) — Clinical and regulatory progress is essential for turning platform science into approved products. - **Leverage PIKA® technology platform** (medium-term) — A proprietary platform can improve differentiation and support multiple product candidates. - **Strengthen corporate and funding structure** (short-term) — Biopharma development requires capital and may benefit from a structure that supports financing and strategic flexibility. - Advance vaccine and therapeutic biologic pipelines - Use PIKA® platform to differentiate immunology programs - Pursue infectious disease and oncology markets - Secure financing and ownership flexibility through transaction activity - Develop manufacturing and delivery capabilities for commercialization ## Risks The company faces development-stage biopharma risks, including clinical trial failure, regulatory delays, and commercialization uncertainty for vaccine and biologic candidates. It is also exposed to cross-border operating and financing risk because its core operations are in China while its securities reporting and investor base are linked to the United States. - **Clinical development failure** [critical] — Biopharmaceutical candidates may not meet efficacy or safety endpoints in trials. - **Regulatory approval delays** [high] — Vaccines and biologics require extensive review by health authorities before commercialization. - **Manufacturing and quality control** [high] — Biologics are sensitive to process consistency, yield, and compliance requirements. - **China-U.S. cross-border exposure** [medium] — Operations in China and reporting/access to U.S. capital markets can create legal, governance, and market-access complexity. - Clinical trial failure could stop key vaccine or biologic programs - Regulatory approval risk is high for infectious disease and oncology products - Manufacturing quality and scale-up issues can delay commercialization - Cross-border governance and financing risk from China-U.S. structure - Competitive pressure from larger vaccine and biologics developers ## Accounting For a biopharma company like LakeShore, the main accounting judgments usually involve R&D capitalization policy, clinical-stage asset valuation, and whether any platform or acquired intangibles should be impaired. Because revenue may depend on licensing, collaboration, or product commercialization timing, investors should watch how the company recognizes milestone or contract-related income and how it treats development costs and contingent obligations. - **Research and development expenses** — Affects operating expense profile and comparability across periods - **Revenue recognition from collaborations** — Can shift revenue between periods - **Intangible asset impairment** — May create large non-cash charges - **Lease accounting** — Affects balance sheet leverage and expense profile - R&D expense recognition affects operating loss timing - Milestone or collaboration revenue may depend on contract terms - Intangible asset impairment risk is significant for development assets - Fair value estimates may affect acquired IP or contingent liabilities - Lease accounting matters for lab and office facilities --- *Last updated: 2026-09-28T12:04:17.021800+00:00*